Platform Introduction: InnoModels PBMC-T Platform — Optimizing PBMC Model Reconstruction and Immune Tumor Research
 
Background and Introduction:
Welcome to InnoModels' PBMC-T Platform, where we are dedicated to optimizing the reconstruction of Peripheral Blood Mononuclear Cell (PBMC) models and conducting immune tumor research. We have successfully addressed the key challenges posed by the interplay between tumor growth and PBMC in immune system tumor models, as well as the difficulty of aligning their respective cycles. As a result, we have significantly increased experimental success rates and overcome the challenges associated with the short dosing window caused by Graft-Versus-Host Disease (GVHD).
 
Key Advantages:
High Success Rate and Stable Reconstruction:
One of our proudest achievements is that our PBMC model experiments boast a success rate of over 85%, with an exceptionally stable reconstruction process. This high success rate and stability ensure the reliability of experimental data and provide a robust foundation for research.
 
Optimized Integration of PBMC and Tumor Models:
A major challenge in human immune system tumor models is the antagonistic interaction between tumor growth and PBMC, exacerbated by the difficulty of synchronizing their cycles, leading to an amplified problem of a short dosing window due to GVHD. Through in-depth research and innovative optimization, InnoModels has successfully tackled this issue, enabling concurrent growth of tumor cells and PBMC. This significantly enhances the operational feasibility and success rate of experiments.
 
Precise Tumor Cell Inoculation Timing:
InnoModels has substantially refined the PBMC reconstruction method, enabling animals to be included in studies within 10-12 days after PBMC inoculation (reconstructed to over 1%). Researchers can now easily determine the timing for tumor cell inoculation, ensuring simultaneous growth of tumors and PBMC to circumvent the challenge of a short dosing window.
 
Extended Dosing Window:
By streamlining experimental protocols, we have successfully extended the dosing window to over 3 weeks, providing greater flexibility and a broader time frame for immune tumor research. This extension facilitates deeper exploration of the interaction between the immune system and tumors, as well as treatment strategies.
 
Compatibility with Majority of Tumor Cells:
InnoModels' PBMC-T Platform is compatible with a majority of tumor cells. More than 90% of human tumor cells can be selected from a single pre-experiment from three PBMC donors for the construction of a shared model.
 
Leading through Innovation:
InnoModels is committed to optimizing PBMC model reconstruction methods and overcoming challenges in immune tumor models, offering exceptional tools to drive advancements in immune tumor research. Our platform stands out in this field with its high success rate, stable reconstruction, optimized tumor-PBMC integration strategy, and extended dosing window. We provide reliable support and innovative leadership for research endeavors.
 
Case examples：
Case 1：
The treatment with anti-Treg agents, including CD25 antibody and IL-2, has demonstrated significant efficacy in KAPPAS299 xenografts within PBMC humanized immune system mice. This was achieved through the establishment of a model platform, termed HuPBMC-T, which facilitates a more comprehensive evaluation of potential therapeutic interventions.

Case2:
Utilizing the innovative PBMC-T model, both single-agent treatments with PD-1 and GARP antibodies, as well as their combination therapy, have demonstrated favorable pharmacological effects and synergistic actions in the JEKO-1 xenograft model within PBMC humanized immune system mice.

Case3：
Leveraging the innovative PBMC-T model, the bispecific antibody targeting both 4-1BB and EGFR demonstrated favorable pharmacological effects in the NCI-H292 xenograft model within PBMC humanized immune system mice. A significant dose-response relationship was observed across various dosage groups, indicating a promising therapeutic potential.
 

Case 4:
Based on the iHuPBMC-T platform, a human immune system was established on the OVCAR-3 cell transplant model to test cytokine-based drugs. Significant pharmacological effects were observed, with a notable enhancement in immune reconstitution in the treated group, resulting in favorable drug efficacy. However, a more severe occurrence of Graft Versus Host Disease (GVHD) was also triggered.